Ling Li et al. screened 129 anti-tumor drugs using patient-derived liver cancer organoids and found significant differences in the efficacy of clinically used drugs, such as sorafenib and gemcitabine, among patients with PLC (Li L. et al., 2019). The gene discussed is HSPG2; the disease is neoplasm.